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Abstract  
BACKGROUND: Noninvasive mechanical ventilation (NIV) applies ventilator support through the 
patient’s upper airway using a mask.  
AIM: The aim of the study is to define factors that will point out an increased risk of NIV failure in 
patients with exacerbation of Chronic Obstructive Pulmonary Disease (COPD).  
PATIENTS AND METHODS: Patients over the age of 40, treated with NIV, were prospectively 
recruited. After data processing, the patients were divided into two groups: 1) successful NIV treat-
ment group; 2) failed NIV treatment group. 
RESULTS: On admission arterial pH and Glasgow coma scale (GCS) levels were lower (pH: p < 
0.05, GCS: p < 0.05), and Acute Physiology and Chronic Health Evaluation II (APACHE) score and 
PaCO2 were higher (p < 0.05) in the NIV failure group. Arterial pH was lower (p < 0.05) and PaCO2 
and respiratory rate were higher (p < 0.05) after 1h, and arterial pH was lower (p < 0.05) and 
PaCO2 (p < 0.05), respiratory and heart rate were higher (p < 0.05) after 4h in the NIV failure group.  
CONCLUSION: Measurement and monitoring of certain parameters may be of value in terms of 
predicting the effectiveness of NIV treatment. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Chronic Obstructive Pulmonary disease 
(COPD) is one of the commonest diseases in the 
world. It is an increasing international health problem 
with a projected third leading cause of mortality within 
the adult population [1]. Chronic obstructive pulmo-
nary disease is a respiratory disorder largely caused 
by smoking, and is characterized by progressive, par-
tially reversible airway obstruction and lung hyperinfla-
tion, systemic manifestations, and increasing fre-
quency and severity of exacerbations. An acute exac-
erbation is defined as a sustained worsening of dysp-
nea, cough or sputum production leading to an in-
crease in the use of maintenance medications and/or 
supplementation with additional medications [2]. The 
management of the acute exacerbations of COPD 
accounts for a large proportion of the health care 
costs because of the need for prolonged hospitaliza-
tions and increased rate of mortality [3]. An important 
event in the course of the disease is the shortening of 
the inspiratory time, leading to a decrease of the Total 
Lung Capacity (TLC) and increase of the respiratory 
rate. The management which aims to increase the 
TLC with subsequent increase in the alveolar ventila-
tion, as well as the decrease of the respiratory rate, is 
expected to reverse the impaired respiratory physiolo-
gy [4]. 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  656                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
The conventional management includes con-
tinuous oxygen therapy and treatment of the underly-
ing cause of the exacerbation in order to decrease the 
airway resistance by using bronchodilators, anti-
inflammatory drugs, oxygen and antibiotics.  
The physiological benefit from the oxygen 
supplementation is represented by the decrease in the 
hypoxic pulmonary vasoconstriction, decrease of the 
pulmonary arterial pressure, thus preventing the right 
heart strain and cardiac ischemia. 
The oxygen supplementation may worsen the 
hypercapnia, and according to some authors in terms 
of this occurrence, the dominant role has the in-
creased ‘dead space’, therefore leading to the ventila-
tion/perfusion mismatch. Unfortunately, there is limited 
possibility to reverse the worsened condition by 
standard management, whereas it was not long ago 
when the sole alternative has been the invasive me-
chanical ventilation associated with a large number of 
complications and side effects. 
In the recent two decades there is particular 
interest towards the usage of Noninvasive ventilation 
(NIV) in the management of acute exacerbations of 
COPD (AECOPD) that require inpatient treatment. 
NIV applies ventilator support through the patient’s 
upper airway using a mask, without endotracheal in-
tubation and represents alternative to the manage-
ment with invasive ventilation in patients with 
hypercapnic respiratory failure (type II).  
NIV is an intermittent model of ventilatory 
support which lasts from few hours per day (6-12 h), 
allowing the patient to be fed, and he/she is able to 
speak. Moreover, the usage of NIV correlates with 
decrease of the complication rate, especially hospital-
acquired pneumonia (in comparison with the intubated 
patients) [12], as well as decrease in the rate of intu-
bations [7, 9, 11] and mortality [7, 8, 11]. 
NIV is not always successful. The failure rate 
is estimated between 5-40% [5]. Treatment failure is 
commonly due to the fact that the disease is in its 
terminal phase. Nevertheless, the clinician’s experi-
ence and expertise are associated with higher rate of 
success [6]. However, in case of increased need for 
ventilatory support, the tolerance of the mask be-
comes limited, which may be the reason for treatment 
failure. According to some authors, the NIV tolerance 
is the sole prognostic factor [13].
  
The aim of the study is to define the clinical 
and laboratory indicators that will point out an in-
creased risk of worsening the condition and treatment 
failure, during NIV treatment of patients with acute 
respiratory failure due to AECOPD. That will enable 
urgent implementation of adequate medical actions 
leading to decreasing mortality. The continuation of 
NIV treatment in patients with no evident success may 
delay the invasive mechanical ventilation that will lead 
to increased mortality.  
Patients and methods 
 
Between October, 2013 and March, 2014, 58 
patients, over the age of 40, hospitalized because of 
acute exacerbation of COPD and treated with NIV 
were prospectively recruited from University Clinic of 
Pulmonology and Allergy- Skopje. The COPD diagno-
sis has been established according to the current 
guidelines [14].
 
 
- Inclusion criteria: severe dyspnea (mMRC scale 
= 3 or 4); respiratory rate > 25/min; hypoxemia 
(PaO2 < 7.3 kPa); hypercapnia (РаСО2 > 6.1 
kРа); respiratory acidosis (pH < 7.35). 
- Exclusion criteria: indication for emergent endo-
tracheal intubation (respiratory or cardiac arrest); 
Glasgow coma scale < 8; hemodynamic instability 
(hypovolemic shock; acute cardiac ischemia; ar-
rhythmias), impaired consciousness; confusion, 
agitation, face or chest trauma, recent surgical in-
tervention of the face, upper airway and upper 
gastrointestinal tract; fixed obstruction of the up-
per airway, vomiting; APACHE II > 29; pregnancy.  
 
Protocol for performing NIV 
Firstly, patients were treated with medications and 
oxygen therapy using nasal cannula no more than one 
hour. Patients that didn’t improve in terms of acid-
base status were initiated with NIV treatment. 
NIV was carried out through a ventilatory support 
system (BiPAP ST/D, Respironiks). Patient was posi-
tioned in a semi-upright sitting position (45
o 
degrees) 
in order to minimize the risk of pulmonary aspiration. 
Oronasal or face mask has been used. Expiratory 
pressure has been at its minimum (4 cmH2O), while 
the inspiratory pressure was at 10 cmH2O. The inspir-
atory pressure had been increased for 2 cmH2O in all 
patients, until the patient showed signs of discomfort 
(dyspnea) or increased air leak out of the face mask 
occurred, or until the pressure of 20 cmH2O was 
reached. Similarly, the expiratory pressure had been 
raised, that is, until the appearance of discomfort or 
the pressure of 7 cmH2O was reached. The oxygen 
had been delivered until the saturation was 90%. The 
NIV treatment has been carried out during three days 
or more, depending of the clinical indications.  
The treatment failure has been defined as 
death or necessity of invasive mechanical ventilation. 
Its manifestations were worsening of the clinical pic-
ture that is, worsening of: 1) pH < 0.04 and PaCO2 > 
0.08; 2) coma or seizure disorders; 3) haemodynamic 
instability (heart rate < 50 bpm/and or systolic blood 
pressure < 70 mmHg; and 4) agitation and inability to 
tolerate the mask.  
The treatment success has been defined as 
improvement in the acid-base, as well as clinical sta-
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tus and reversal of the condition at the level present 
before the exacerbation. Thus, oxygen saturation was 
expected to be measured > 85% without nasal cannu-
la (i.e. > 90% with nasal cannula and oxygen 1-2 
L/min); pH > 7.35; RR < 25/min. without the engage-
ment of the accessory respiratory musculature. The 
commencement of weaning from the NIV was per-
formed with greater pauses during the day or the NIV 
was used only during the night.  
The following data were analyzed: demo ex-
acerbation; Glasgow Coma Scale (GCS); Acute Phys-
iology and Chronic Health Evaluation (APACHE) II 
score; Respiratory Rate (RR); pH; partial pressure of 
oxygen (PaO2); partial pressure of carbon dioxide 
(PaCO2). Arterialized blood sample was drawn from 
earlobe and acid-base status was evaluated at the 
beginning of NIV treatment, 1 hour and 4 hours after, 
and at the end of the treatment. 
 
Statistical analysis 
The results were statistically analysed accord-
ing to the Difference test .The results were expressed 
as mean ± standard deviation. The significances val-
ues were taken p < 0.05.  
 
 
Results 
 
Out of 85 patients hospitalized because of 
respiratory failure due to AECOPD, 58 patients have 
met the inclusion criteria. The treatment success was 
recorded in 40 patients (68.9%), whereas treatment 
failure was a case in 18 patients out of the total num-
ber. There was no correlation between the patients’ 
demographics and the treatment’s failure. Treatment 
complications where observed in two patients with 
ulcerations on the bridge of the nose and conjunctivitis 
in one patient. These complications where overcame 
by changing the mask. 
Table 1: Demographic and laboratory characteristics at admis-
sion 
Total patients randomized  58 
Age (main  ± SD)  65.6 ± 9 
Sex (male) [n(%)]  48 (82.7%) 
Cause of exacerbation [No (%)] 
Upper respiratory tract infections including 
bronchitis  
38 (65.5%) 
Pneumonia 7 (12%) 
Other  8 (13.7) 
Co-morbidities [n(%)] 
CVDs*  36 (62%) 
Diabetes Mellitus  7 (12.0%) 
Obesity  19 (32.7) 
Hypertension  28 (48.2) 
Cachexia  2 (3.4%) 
Respiratory rate (main ± SD)  32.5 ± 5 
Heart rate (bpm) (main  ± SD)  112 ± 8 
pH (main ± SD)  7.25 ± 0.08 
PaO2 kPa (main ± SD)  6.2 ± 1.0 
PaCO2 kPa (main ± SD)  9.7  ±  2.4 
APACHE** II (main ± SD)  18.3 ± 6.1 
GSC*** (main ± SD)  12.2 ± 2.8 
APACHE** = Acute Physiology and Chronic Health Evaluation; CVD* = cardiovascular 
diseases; GCS***, Glasgow coma scale. 
Upon data processing, patients were divided 
into two groups: Group 1 – successful NIV treatment 
and Group 2 – failed NIV treatment. 
Table 2: Comparison of the clinical and laboratory characteris-
tics between both groups at the time of admission, Group 1 
and Group 2 
Parameters Group1 
successful NIV 
( n=40) 
Group 2 
failed NIV 
(n=18) 
р-value 
Respiratory rate  32.3 ± 3.2 34.5 ± 3.0 NS 
Heart rate  110 ± 6.1 115 ± 5.2 NS 
pH 7.30 ± 0.03 7.23 ± 0.06 p < 0.05 
PaO2 kPa  6.3 ± 0.9 6.2 ± 1.0 NS 
PaCO2 kPa  8.2 ± 0.9 10.5 ± 1.6 p < 0.05 
APACHE* II  16.2 ± 4.0 21.4 ± 3.0 p < 0.05 
GSC**  14.0 ± 1.0 11.6 ± 1.2 p<0.05 
APACHE*= Acute Physiology and Chronic Health Evaluation; GCS** = Glasgow coma 
scale; NIV = Noninvasive ventilation; NS-nonsignigicant. 
 
In patients with successful NIV treatment 
there is significantly higher initial GCS score, in-
creased blood pH, lower APACHE II score and de-
creased PaCO2. 
Table 3: Comparison of the clinical and laboratory characteris-
tics between both groups at 1 and 4 h 
Parameters Group1 
successful NIV 
( n=40) 
Group 2 
failed NIV 
(n=18) 
р-value 
After 1 hour 
Respiratory rate  23.5 ± 6.2 35.5 ± 3.0 p < 0.05 
Heart rate  109.3 ± 6.9 117 ± 7.9 NS 
pH 7.32 ± 0.06 7.22 ± 0.07 p < 0.05 
PaO2 kPa  7.5 ± 0.9 7.4 ± 0.5 NS 
PaCO2 kPa  8.0 ± 0.8 11.5 ± 1.2 p < 0.05 
Parameters Group1 
successful NIV 
( n=40) 
Group 2 
failed NIV 
(n=18) 
р-value 
After 4 hours 
Respiratory rate  24.1 ± 3.2 34.8 ± 3.5 p < 0.05 
Heart rate  95.9 ± 6.1 118 ± 5.4 p < 0.05 
pH 7.33 ± 0.05 7.21 ± 0.04 p < 0.05 
PaO2 kPa  7.9 ± 0.5 7.8 ± 0.4 NS 
PaCO2 kPa  7.2 ± 0.5 10.5 ± 1.6 p < 0.05 
 
On admission arterial pH and Glasgow coma 
scale (GCS) levels were lower (pH: p<0.05, GCS: p < 
0.05), and Acute Physiology and Chronic Health Eval-
uation II (APACHE) score and PaCO2 were higher (p 
< 0.05) in the NIV failure group. Arterial pH was lower 
(p < 0.05) and PaCO2and respiratory rate were higher 
(p < 0.05) after 1h, and arterial pH was lower (p < 
0.05) and PaCO2 (p < 0.05), respiratory and heart 
rate were higher (p < 0.05) after 4h in the NIV failure 
group (Fig. 1, 2, 3).  
 
Figure 1: pH pre and post NIV 
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Figure 2: PaCO2 pre and post NIV 
 
Out of the results we may conclude that: GCS 
< 12, APACHE II > 24, pH < 7.29, PaCO2 >10.0 kPa 
at admission, as well as RR > 30/min, pH < 7.25, 
PaCO2 > 10.5 kPa, at the first hour, is in close correla-
tion with treatment failure. During the 4 hour this per-
tains to RR > 30/min, pH < 7.24, PaCO2 >11.0 kPa, 
and HR >100/min. 
 
Figure 3: Respiratory rate pre and post NIV 
 
In the group with failed NIV treatment, there 
was a 33.3% mortality rate, that is, in total there was a 
lethal outcome in six patients, while in the other group 
was not observed lethal outcome. 
 
 
Discussion  
 
According to the recommendations of the 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD), the commencement of the NIV treatment is 
needed in every patient with decompensated COPD 
that fulfils the criteria for it [15].
 
During the follow-up if 
the treatment success, being aware of the predictive 
factors that eventually point out treatment failure, shall 
help in the decision-making in terms of whether the 
NIV treatment should be continued, that is, whether a 
shift in the treatment modality should be done. This is 
important, if we take into account that any delay of the 
intubation can lead to a negative outcome [27, 28].
 
The results of the conducted study have 
shown that in 68.9% of patients with decompensated 
COPD, a successful treatment with NIV was achieved, 
whereas in 18 patients there was a treatment failure 
(early failure in the first 48 hours of the treatment with 
NIV in 12 patients (20.6%) and late failure after 48 
hours in six patients (10.3%)). Up to now, the con-
ducted studies have revealed that the success rate 
with NIV ranges between 60-90% [9, 16-20], despite 
the fact that there are studies showing no effect with 
NIV in comparison with standard treatment [21]. The 
mortality rate in our study was estimated 33.3% in the 
group comprising the failed NIV treatment, in particu-
lar. Morreti et al., [24] in a study which had included a 
total of 137 patients treated with NIV because of acute 
exacerbation of COPD, the condition of 106 (77%) 
patients improved. The condition was worsened in 
23% of patients, out of which, those who were 
switched on mechanical ventilation, a mortality rate 
was 53% against 92%, which is the mortality rate of 
patients who continued the NIV treatment.  
In our study, age did not correlated with the 
NIV treatment effectiveness, which corresponds with 
the other authors’ findings [22, 23], leading to the con-
clusion that age should not be considered as a limiting 
factor for NIV treatment. We have analyzed and com-
pared the results of both groups on admission, 
whereas we drew a conclusion that patients in the 
group with successful NIV treatment have significantly 
higher values of arterial pH and GCS and lower val-
ues for PaCO2 and APACHE II score, in comparison 
with the other group with failed NIV treatment. The 
analyzes made one hour after the NIV treatment re-
vealed higher values for the arterial pH and lower for 
the respiratory rate (RR) and PaCO2 in the successful 
NIV treatment group. Four hours after the NIV treat-
ment, the arterial pH was higher, while PaCO2, RR 
and HR were lower in the successful against the failed 
NIV treatment group. 
According to the findings of our study, that are 
corresponding to the findings of many other similar 
studies, the starting point for patient identification that 
could benefit from NIV treatment should be the degree 
of acidosis. Furthermore, the improvement of this pa-
rameter at the first hours of the treatment, along with 
the decrease in respiratory rate is a predictor for a 
positive outcome [29]. According to Abrosino et al., 
[20] the initial pH has significant predictive value with 
sensitivity of 97% and specificity of 71%.  
Antonio et al., [24] after analyzing 44 episodes of 
hypercapnic respiratory failure has found high correla-
tion of the NIV treatment outcome with the PaCO2, pH 
and the level of consciousness one hour after the ven-
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tilation. The improvement of the level of conscious-
ness, which is most probably a consequence of the 
PaCO2 decrease one hour after the NIV treatment, 
has shown strong correlation as well. Identical to the 
study of Ambrosino et al., [20], our study findings re-
vealed higher GCS score in patients from the suc-
cessful NIV treatment group against the failed NIV 
group that is in accordance with the American Thorac-
ic Society (ATS) consensus [25] stating that the al-
tered state of consciousness should be relative con-
traindication for NIV. 
In conclusion, in this study, being conducted 
for the first time in the field of NIV in our country, we 
aimed to present our experiences. We concluded that 
the measurement of certain parameters, especially 
pH, respiratory rate, PaCO2 and the state of con-
sciousness may be of value in terms of predicting the 
effectiveness of NIV treatment, in order to avoid the 
delay the treatment with invasive mechanical ventila-
tion, thus enabling better clinical management of the 
affected patients. We believe that the further studies 
carried out in this field and the increasing experience 
of clinicians will lead to a better effectiveness of the 
NIV treatment.  
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